Erythropoietin, Gadolinium, and Nephrogenic Fibrosing Dermopathy
Authors: Richard N. Hellman
Journal: Annals of Internal Medicine (2007)

Letters6 February 2007Erythropoietin, Gadolinium, and Nephrogenic Fibrosing DermopathyRichard N. Hellman, MDRichard N. Hellman, MDFrom Indiana University, Indianapolis, Indiana.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-146-3-200702060-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR: I read with great interest the article by Swaminathan and colleagues (1) on the possible role of erythropoietin in 22 patients with nephrogenic fibrosing dermopathy. Of interest were the temporal relationship to erythropoietin use, apparent association compared with a control group of higher doses of erythropoietin, and improvement in some patients with erythropoietin dosage reduction. Recent advisories from the U.S. Food and Drug Administration (2) and the Danish Medicines Agency (3) and an article by Grobner (4) have suggested an association between nephrogenic fibrosing dermopathy and gadolinium use in patients with stage 5 or 6 chronic kidney ...References1. Swaminathan S, Ahmed I, McCarthy JT, Albright RC, Pittelkow MR, Caplice NM, et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy [Letter]. Ann Intern Med. 2006;145:234-5. [PMID: 16880475] LinkGoogle Scholar2. U.S. Food and Drug Administration. Information for healthcare professionals: gadolinium-containing contrast agents for magnetic resonance imaging (MRI) (marketed as Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance). Rockville, MD: U.S. Food and Drug Administration; June 2006. Accessed at www.fda.gov/cder/drug/InfoSheets/HCP/gccaHCP.pdf on 18 December 2006 Google Scholar3. Danish Medicines Agency. Investigation of the safety of MRI contrast medium Omniscan [press release]. Copenhagen: Danish Medicines Agency; 29 May 2006. Accessed at www.dkma.dk/1024/visUKLSArtikel.asp?artikelID=8931 on 18 December 2006 Google Scholar4. Grobner T. Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104-8. [PMID: 16431890] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Richard N. Hellman, MDAffiliations: From Indiana University, Indianapolis, Indiana.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoNephrogenic Fibrosing Dermopathy and High-Dose Erythropoietin Therapy Sundararaman Swaminathan , Iftikhar Ahmed , James T. McCarthy , Robert C. Albright , Mark R. Pittelkow , Noel M. Caplice , Matthew D. Griffin , and Nelson Leung Erythropoietin, Gadolinium, and Nephrogenic Fibrosing Dermopathy Nelson Leung , Sundararaman Swaminathan , Iftikhar Ahmed , James T. McCarthy , Robert C. Albright , Mark R. Pittelkow , Noel M. Caplice , and Matthew D. Griffin Metrics Cited byGadolinium-Based Contrast Exposure, Nephrogenic Systemic Fibrosis, and Gadolinium Detection in TissueGadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injuryNSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Early Recognition and Treatment 6 February 2007Volume 146, Issue 3Page: 229-230KeywordsAcidosisChronic kidney diseaseConflicts of interestErythropoietinEtiologyFood and Drug AdministrationInflammationMagnetic resonance angiography ePublished: 6 February 2007 Issue Published: 6 February 2007 Copyright & PermissionsCopyright © 2007 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...